Endocrinology post
New study finds high dose tofacitinib is safe and effective in COVID patients with pneumonitis and may prevent deterioration to respiratory failure. Open-labelled study with 116 patients, 15.5% of tofacitinib group progressed to non-invasive ventilation, compared to 29.3% in control group. Published in European Journal of Clinical Investigation.